Research Coverage of Japanese Listed Companies, Shared Research Inc

Shared Research

Research Coverage of Japanese Listed Companies

Shared Research Inc

Pioneering research coverage of Japanese listed companies. Now customizable and interactive for global institutional investors. Corporate access reimagined.

Equity Bottom-Up

<ul><li>Revenue for FY10/24 was JPY4.4bn, a 3.4% YoY decrease, with operating profit down 89.4% YoY to JPY129mn. </li><li>FY10/25 forecasts include revenue of JPY4.5bn (+3.4% YoY) and operating profit of JPY370mn (+186.5% YoY). </li><li>Contract processing services revenue declined 12.8% YoY in FY10/24, with orders decreasing by 13.9% YoY.</li></ul>

Revenue for FY10/24 was JPY4.4bn, a 3.4% YoY decrease, with operating profit down 89.4% YoY to JPY129mn. FY10/25 forecasts include revenue of JPY4.5bn (+3.4% YoY) and operating profit of JPY370mn (+186.5% YoY). Contract processing services revenue declined 12.8% YoY in FY10/24, with orders decreasing by 13.9% YoY.

CellSource   (4880 JP): Full-year FY10/24 flash update

<ul><li>Revenue: JPY3.3bn (-1.9% YoY), Operating profit: JPY388mn (-62.8% YoY), Recurring profit: JPY496mn (-52.3% YoY), Net income: JPY374mn (-44.6% YoY).</li><li>Contract processing services revenue: JPY2.0bn (-12.9% YoY), Consulting services revenue: JPY161mn (-54.9% YoY), Medical device sales: JPY711mn (+35.4% YoY), Cosmetics sales: JPY419mn (+145.0% YoY).</li><li>Revised earnings forecast for FY10/24: Revenue JPY4.4bn (-3.0% YoY), Operating profit JPY420mn (-65.6% YoY), Recurring profit JPY527mn (-55.9% YoY), Net income JPY417mn (-54.8% YoY).</li></ul>

Revenue: JPY3.3bn (-1.9% YoY), Operating profit: JPY388mn (-62.8% YoY), Recurring profit: JPY496mn (-52.3% YoY), Net income: JPY374mn (-44.6% YoY).Contract processing services revenue: JPY2.0bn (-12.9% YoY), Consulting services revenue: JPY161mn (-54.9% YoY), Medical device sales: JPY711mn (+35.4% YoY), Cosmetics sales: JPY419mn (+145.0% YoY).Revised earnings forecast for FY10/24: Revenue JPY4.4bn (-3.0% YoY), Operating profit JPY420mn (-65.6% YoY), Recurring profit JPY527mn (-55.9% YoY), Net income JPY417mn (-54.8% YoY).

CellSource   (4880 JP): Q3 FY10/24 flash update

Japan

CellSource Co., Ltd. offers regenerative medical services. The Company provides medical institution operating procedures supporting, medical expertise knowledge supporting, and other services. CellSource also operates chemical manufacturing, cell processing, and other businesses.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

CellSource (4880 JP)

CellSource (4880 JP): Full-year FY10/24 flash update

Revenue for FY10/24 was JPY4.4bn, a 3.4% YoY decrease, with operating profit down 89.4% YoY to JPY129mn. FY10/25 forecasts include revenue of...

Shared Research

CellSource (4880 JP): Q3 FY10/24 flash update

Revenue: JPY3.3bn (-1.9% YoY), Operating profit: JPY388mn (-62.8% YoY), Recurring profit: JPY496mn (-52.3% YoY), Net income: JPY374mn (-44.6%...

Shared Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)